User profiles for Graham P Collins
 | Graham CollinsOxford Verified email at ouh.nhs.uk Cited by 10489 |
[HTML][HTML] CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma
…, M Roschewski, A LaCasce, GP Collins… - … England Journal of …, 2018 - Mass Medical Soc
Background The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint
inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab …
inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab …
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
…, M Marchetti, GP Collins… - Journal of hematology & …, 2021 - Springer
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …
[HTML][HTML] Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the …
…, PL Zinzani, JM Timmerman, GP Collins… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Genetic alterations causing overexpression of programmed death-1 ligands are
near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 …
near universal in classic Hodgkin lymphoma (cHL). Nivolumab, a programmed death-1 …
[HTML][HTML] Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin …
…, PL Zinzani, J Timmerman, GP Collins… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means,
including gains of 9p24. 1/CD274 (PD-L1)/PDCD1LG2 (PD-L2) and perturbed antigen …
including gains of 9p24. 1/CD274 (PD-L1)/PDCD1LG2 (PD-L2) and perturbed antigen …
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
…, F Morschhauser, GP Collins… - Blood, The Journal …, 2017 - ashpublications.org
Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no
standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell …
standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell …
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase …
…, A McMillan, P Fields, C Pocock, GP Collins… - The Lancet …, 2019 - thelancet.com
Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
…, L Robinson, A O'Callaghan, GP Collins… - Nature cancer, 2022 - nature.com
Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes
due to compromised immune responses, but the insights of these studies have been …
due to compromised immune responses, but the insights of these studies have been …
Computing with quantum knots
GP Collins - Scientific American, 2006 - JSTOR
uantum computers promise to perform calculations believed to be impossible for ordinary
computers. Some of those calculations are of great real-world importance. For example, certain …
computers. Some of those calculations are of great real-world importance. For example, certain …
Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
…, M Johnson, D Joseph-Pietras, GP Collins… - The Lancet …, 2021 - thelancet.com
Individuals with lymphoid malignancies are at risk of developing severe COVID-19 and are
less likely to develop protective immune responses to SARS-CoV-2 vaccination than the …
less likely to develop protective immune responses to SARS-CoV-2 vaccination than the …
A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience
…, K Robinson, A Pagliuca, GP Collins… - British Journal of …, 2022 - Wiley Online Library
CD19 CAR‐T have emerged as a new standard treatment for relapsed/refractory (r/r) large B‐cell
lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date suggest …
lymphoma (LBCL). CAR‐T real‐world (RW) outcomes published to date suggest …
